Cystic fibrosis gene therapy - Inex Pharmaceuticals
Latest Information Update: 16 Dec 1998
At a glance
- Originator Inex Pharmaceuticals Corporation
- Developer Inex Pharmaceuticals Corporation; The Hospital for Sick Children
- Class Gene therapies
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cystic fibrosis
Most Recent Events
- 16 Dec 1998 Discontinued-Preclinical for Cystic fibrosis in Canada (Unknown route)
- 28 Oct 1997 Preclinical development for Cystic fibrosis in Canada (Unknown route)